Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Nuwellis Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.51 (market cap $2.98B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is far larger — about 1354.5× Nuwellis Inc's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Nuwellis Inc for 26 Days on average.
| FNGU | NUWE | |
|---|---|---|
Market Cap | $2.98B | $2.20M |
Volume | 4,682,352 | 121,544 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $146.65 |
52-Week Low | $13.73 | $0.68 |
Typical Hold Time | 19 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.31, down 2.39% today. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETN faces significant volatility risks, having lost 87% during previous tech sector downturns according to 247 Wallst analysis from August 19, 2026.
The outlook remains highly speculative given the leveraged structure. While bullish technicals suggest near-term upside potential to resistance at $37-39, the extreme volatility and concentration in mega-cap tech stocks present substantial downside risks during market corrections. Investors require high risk tolerance for this instrument.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
